(85.8%) were biopsy-proven. Most cases involved patients with Stage 4 or 5
CKD, although in 14 cases the patient suffered from acute renal failure.
Patients receiving only Omniscan or Magnevist accounted for 93.3% of reported
NSF cases. The most commonly administered gadolinium doses were 0.2-0.29
mmol/kg. In most cases, symptoms appeared 1-3 months after the last
administration of gadolinium contrast. Importantly, no cases with an onset
after 2007 were identified, suggesting changes in practice patterns have
largely eliminated this disease.